Ftse Mib
33.707,21
-0,38%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
62.144,32
0,55%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ 4D Molecular Therapeutics Inc (FDMT) 4D Molecular Therapeutics Inc (FDMT) Notizie

4D Molecular Therapeutics Inc

FDMT
22,00
-1,25 (-5,38%)
26 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/6/202414:00GLOBE4DMT Announces FDA Clearance of IND Application for 4D-175..
18/6/202414:00GLOBE4DMT to Present Initial Interim 24-week Landmark Analysis..
08/6/202422:30GLOBE4DMT Presents Injection-Free Subgroup Analyses from 4D-150..
07/6/202423:07EDGAR2Form 8-K - Current report
07/6/202423:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/6/202413:30GLOBE4DMT Presents Positive Interim Data from Phase 1/2 AEROW..
04/6/202414:00GLOBE4DMT Announces Presentations at Clinical Trials at the..
03/6/202414:00GLOBE4DMT to Participate in Upcoming Investor Conferences
30/5/202414:00GLOBE4DMT to Present Interim Data from Aerosolized 4D-710 Phase..
24/5/202422:28EDGAR2Form 8-K - Current report
24/5/202401:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202401:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202402:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:22EDGAR2Form 8-K - Current report
09/5/202422:05GLOBE4DMT Reports First Quarter 2024 Financial Results and..
07/5/202414:00GLOBE4DMT to Participate in Upcoming Investor Conference
01/5/202414:00GLOBE4DMT Announces Presentations at ARVO 2024 Annual Meeting
28/3/202413:00GLOBE4DMT Announces Update on Regulatory Interactions and..
04/3/202414:00GLOBE4DMT to Participate in Upcoming Investor Conferences
01/3/202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202423:15EDGAR2Form S-8 - Securities to be offered to employees in employee..
29/2/202422:12EDGAR2Form 8-K - Current report
29/2/202422:05GLOBE4DMT Reports Full Year 2023 Financial Results and..
21/2/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202402:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202422:37EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202403:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202402:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202414:00GLOBE4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2..
09/2/202422:56EDGAR2Form 8-K - Current report
08/2/202422:50EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/2/202422:22EDGAR2Form 144 - Report of proposed sale of securities
08/2/202402:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202401:42EDGAR2Form 3/A - Initial statement of beneficial ownership of..
07/2/202405:27GLOBE4D Molecular Therapeutics Announces Pricing of Upsized..
05/2/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/2/202422:35EDGAR2Form S-3ASR - Automatic shelf registration statement of..
05/2/202422:05GLOBE4D Molecular Therapeutics Announces Proposed Public Offering..
03/2/202423:00GLOBE4DMT Presents Positive Interim Data from Randomized Phase 2..
29/1/202414:00GLOBE4DMT to Host Corporate Webcast to Discuss Interim Data from..
25/1/202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202422:50EDGAR2Form 144 - Report of proposed sale of securities
23/1/202414:00GLOBE4DMT Receives Rare Pediatric Disease Designation from FDA..
08/1/202422:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:49EDGAR2Form 144 - Report of proposed sale of securities
04/1/202423:48EDGAR2Form 144 - Report of proposed sale of securities
04/1/202414:30EDGAR2Form 8-K - Current report
04/1/202414:00GLOBE4DMT Highlights Recent Clinical Pipeline Progress, Near-Term..
Apertura: 23,14 Min: 21,86 Max: 23,24
Chiusura: 23,25

La tua Cronologia

NASDAQ
FDMT
4D Molecular Therapeutics
NASDAQ
RBI
LSE
TOPE
BIT
P1Y3V3
NLBNPIT1Y3V3 20351219 21...
COIN
SABAIETH
Sabai Ecoverse Token
USOTC
CCPPF
Capital and Counties Pro... (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network